Dr. Macarulla Discusses Rapid Progressors in the POLO Trial in Pancreatic Cancer

Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic CancerПодробнее

Philip Philip MD, PhD, FRCP, discusses outcomes from the POLO trial in pancreatic cancerПодробнее

POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancerПодробнее

Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO...Подробнее

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic CancerПодробнее

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic CancerПодробнее

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic CancerПодробнее

POLO Trial in Pancreatic CancerПодробнее

Dr. Hall Discusses Rationale for the POLO Trial in Metastatic Pancreatic CancerПодробнее

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsПодробнее

[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutationsПодробнее

Future of targeted therapies for non-colorectal GI cancersПодробнее

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-relate...Подробнее

Olaparib in metastatic pancreatic cancer, the POLO trialПодробнее

PARP Inhibitors gBRCA1/2-Mutated Pancreatic CancerПодробнее

Optimizing genomic testing for non-colorectal GI cancersПодробнее

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients wi...Подробнее

Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it downПодробнее

Dr Reber Speaks on Surgical Strategies in Pancreatic CancerПодробнее